

Paul W Jones

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/520570/publications.pdf>

Version: 2024-02-01

85
papers

19,645
citations

94381

37
h-index

58549

82
g-index

85
all docs

85
docs citations

85
times ranked

14953
citing authors

#	ARTICLE	IF	CITATIONS
1	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 347-365.	2.5	7,792
2	Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2007, 356, 775-789.	13.9	2,963
3	A Self-complete Measure of Health Status for Chronic Airflow Limitation: The St. George's Respiratory Questionnaire. The American Review of Respiratory Disease, 1992, 145, 1321-1327.	2.9	2,658
4	Treatable traits: toward precision medicine of chronic airway diseases. European Respiratory Journal, 2016, 47, 410-419.	3.1	746
5	St. George's Respiratory Questionnaire: MCID. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2005, 2, 75-79.	0.7	713
6	Effect of Pharmacotherapy on Rate of Decline of Lung Function in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 332-338.	2.5	692
7	Minimal Clinically Important Differences in Pharmacological Trials. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 250-255.	2.5	360
8	Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respiratory Medicine, the, 2013, 1, 210-223.	5.2	301
9	Blood eosinophils and inhaled corticosteroid/long-acting β_2 -agonist efficacy in COPD. Thorax, 2016, 71, 118-125.	2.7	288
10	Development and Validation of an Improved, COPD-Specific Version of the St. George Respiratory Questionnaire. Chest, 2007, 132, 456-463.	0.4	287
11	Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to Evaluate Severity of COPD Exacerbations. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 1218-1224.	2.5	164
12	Standardizing Measurement of Chronic Obstructive Pulmonary Disease Exacerbations. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 323-329.	2.5	160
13	Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification. European Respiratory Journal, 2013, 42, 647-654.	3.1	153
14	COPD uncovered: an international survey on the impact of chronic obstructive pulmonary disease [COPD] on a working age population. BMC Public Health, 2011, 11, 612.	1.2	123
15	Brain Structure and Function in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 240-245.	2.5	116
16	Corticosteroids for pulmonary sarcoidosis. The Cochrane Library, 2005, , CD001114.	1.5	105
17	Improving the process and outcome of care in COPD: development of a standardised assessment tool. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2009, 18, 208-215.	2.5	103
18	Development of the EXacerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): A Patient-Reported Outcome (PRO) Measure. Value in Health, 2010, 13, 965-975.	0.1	97

#	ARTICLE	IF	CITATIONS
19	Measuring respiratory symptoms of COPD: performance of the EXACT- Respiratory Symptoms Tool (E-RS) in three clinical trials. <i>Respiratory Research</i> , 2014, 15, 124.	1.4	91
20	Analysis of comorbid factors that increase the COPD assessment test scores. <i>Respiratory Research</i> , 2014, 15, 13.	1.4	87
21	Health Status Assessment in Routine Clinical Practice: The Chronic Obstructive Pulmonary Disease Assessment Test Score in Outpatients. <i>Respiration</i> , 2012, 84, 193-199.	1.2	85
22	Beclomethasone versus placebo for chronic asthma. <i>The Cochrane Library</i> , 2005, , CD002738.	1.5	84
23	Predicting EQ-5D Values Using the SGRQ. <i>Value in Health</i> , 2011, 14, 354-360.	0.1	81
24	Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. <i>Respiratory Research</i> , 2019, 20, 238.	1.4	81
25	Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre-“Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 275-287.	2.5	72
26	Characterizing and Quantifying the Symptomatic Features of COPD Exacerbations. <i>Chest</i> , 2011, 139, 1388-1394.	0.4	71
27	Is The CAT Questionnaire Sensitive To Changes In Health Status In Patients With Severe COPD Exacerbations?. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2012, 9, 492-498.	0.7	70
28	Measuring the effects of COPD on the patient. <i>Respiratory Medicine</i> , 2005, 99, S11-S18.	1.3	60
29	Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. <i>Respiratory Research</i> , 2011, 12, 71.	1.4	60
30	Characterisation and impact of reported and unreported exacerbations: results from ATTAIN. <i>European Respiratory Journal</i> , 2014, 44, 1156-1165.	3.1	60
31	The effect of age on the power/duration relationship and the intensity-domain limits in sedentary men. <i>European Journal of Applied Physiology</i> , 2000, 82, 326-332.	1.2	55
32	Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. <i>The Cochrane Library</i> , 2007, , CD002310.	1.5	55
33	Oral theophylline for chronic obstructive pulmonary disease. <i>The Cochrane Library</i> , 2002, , CD003902.	1.5	53
34	One-year change in health status and subsequent outcomes in COPD. <i>Thorax</i> , 2015, 70, 420-425.	2.7	50
35	Performance of the EXacerbations of Chronic Pulmonary Disease Tool Patient-reported Outcome Measure in Three Clinical Trials of Chronic Obstructive Pulmonary Disease. <i>Annals of the American Thoracic Society</i> , 2014, 11, 316-325.	1.5	41
36	The St. George’s Respiratory Questionnaire Definition of Chronic Bronchitis May Be a Better Predictor of COPD Exacerbations Compared With the Classic Definition. <i>Chest</i> , 2019, 156, 685-695.	0.4	40

#	ARTICLE	IF	CITATIONS
37	Cyclosporin as an oral corticosteroid sparing agent in stable asthma. The Cochrane Library, 2000, , CD002993.	1.5	39
38	Role of clinical questionnaires in optimizing everyday care of chronic obstructive pulmonary disease. International Journal of COPD, 2011, 6, 289.	0.9	37
39	Budesonide versus placebo for chronic asthma in children and adults. The Cochrane Library, 1999, , CD003274.	1.5	31
40	Inhaled short acting beta2-agonist use in chronic asthma: regular versus as needed treatment. The Cochrane Library, 2003, , .	1.5	31
41	Changes in plasma levels of B-type natriuretic peptide with acute exacerbations of chronic obstructive pulmonary disease. International Journal of COPD, 2014, 9, 155.	0.9	26
42	Predictors of Mortality in Patients with COPD and Chronic Respiratory Failure: The Quality-of-Life Evaluation and Survival Study (QuESS): A Three-Year Study. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2016, 13, 130-138.	0.7	26
43	Understanding low COPD exacerbation rates in Japan: a review and comparison with other countries. International Journal of COPD, 2018, Volume 13, 3459-3471.	0.9	26
44	Inhaled versus oral steroids for adults with chronic asthma. The Cochrane Library, 2001, , .	1.5	25
45	Rescue medication use as a patient-reported outcome in COPD: a systematic review and regression analysis. Respiratory Research, 2017, 18, 86.	1.4	22
46	Validation of the Airways Questionnaire 20 - AQ20 in patients with chronic obstructive pulmonary disease (COPD) in Brazil. Jornal De Pneumologia, 2003, 29, 28-35.	0.1	21
47	White matter lesions characterise brain involvement in moderate to severe chronic obstructive pulmonary disease, but cerebral atrophy does not. BMC Pulmonary Medicine, 2017, 17, 92.	0.8	21
48	Beclomethasone versus budesonide for chronic asthma. The Cochrane Library, 2002, , CD003530.	1.5	19
49	Risk factors for exacerbations and pneumonia in patients with chronic obstructive pulmonary disease: a pooled analysis. Respiratory Research, 2020, 21, 5.	1.4	19
50	Budesonide at different doses for chronic asthma. The Cochrane Library, 2000, , CD003271.	1.5	18
51	Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD. International Journal of COPD, 2021, Volume 16, 499-517.	0.9	17
52	<p>Contributions of cardiovascular risk and smoking to chronic obstructive pulmonary disease (COPD)-related changes in brain structure and function</p>. International Journal of COPD, 2019, Volume 14, 1855-1866.	0.9	16
53	CAT score single item analysis in patients with COPD: Results from COSYCONET. Respiratory Medicine, 2019, 159, 105810.	1.3	16
54	Gold as an oral corticosteroid sparing agent in stable asthma. The Cochrane Library, 2000, , CD002985.	1.5	15

#	ARTICLE	IF	CITATIONS
55	COPD: the patient perspective. International Journal of COPD, 2016, 11 Spec Iss, 13.	0.9	14
56	<p>Inhaled corticosteroids, blood eosinophils, and FEV<sub>1</sub> decline in patients with COPD in a large UK primary health care setting</p>. International Journal of COPD, 2019, Volume 14, 1063-1073.	0.9	14
57	Carbonic anhydrase inhibitors for hypercapnic ventilatory failure in chronic obstructive pulmonary disease. The Cochrane Library, 2001, , CD002881.	1.5	13
58	Pressurised metered-dose inhalers versus all other hand-held inhalers devices to deliver bronchodilators for chronic obstructive pulmonary disease. The Cochrane Library, 2002, , CD002170.	1.5	13
59	Beclomethasone at different doses for chronic asthma. The Cochrane Library, 1999, , CD002879.	1.5	10
60	Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease. International Journal of COPD, 2015, 10, 677.	0.9	10
61	Troleandomycin as an oral corticosteroid sparing agent in stable asthma. The Cochrane Library, 2000, , CD002987.	1.5	9
62	Clinical Effects of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 2004, 1, 167-170.	3.5	9
63	Cardiovascular Disease Does Not Predict Exacerbation Rate or Mortality in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 400-403.	2.5	9
64	The distribution of blood eosinophil levels in a Japanese COPD clinical trial database and in the rest of the world. International Journal of COPD, 2018, Volume 13, 433-440.	0.9	9
65	A study to assess COPD Symptom-based Management and to Optimise treatment Strategy in Japan (COSMOS-J) based on GOLD 2011. International Journal of COPD, 2013, 8, 453.	0.9	8
66	<p>Evaluating Patient Preferences of Maintenance Therapy for the Treatment of Chronic Obstructive Pulmonary Disease: A Discrete Choice Experiment in the UK, USA and Germany</p>. International Journal of COPD, 2020, Volume 15, 595-604.	0.9	8
67	Treatment of COPD with Long-Acting Bronchodilators: Association Between Early and Longer-Term Clinically Important Improvement. International Journal of COPD, 2021, Volume 16, 1215-1226.	0.9	8
68	Pressurised metered dose inhalers versus all other hand-held inhaler devices to deliver beta-2 agonist bronchodilators for non-acute asthma. The Cochrane Library, 2002, , CD002158.	1.5	7
69	The relationship between the COPD Assessment Test score and airflow limitation in Japan in patients aged over 40 years with a smoking history. International Journal of COPD, 2014, 9, 1357.	0.9	7
70	Development of the chronic obstructive pulmonary disease morning symptom diary (COPD-MSD). Health and Quality of Life Outcomes, 2016, 14, 104.	1.0	7
71	A randomized trial of symptom-based management in Japanese patients with COPD. International Journal of COPD, 2018, Volume 13, 2409-2423.	0.9	7
72	Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-Naïve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX Trial. International Journal of COPD, 2021, Volume 16, 1939-1956.	0.9	6

#	ARTICLE	IF	CITATIONS
73	Clinical Characteristics of COPD Patients According to COPD Assessment Test (CAT) Score Level: Cross-Sectional Study. International Journal of COPD, 2021, Volume 16, 1509-1517.	0.9	6
74	The Development of a COPD Exacerbation Recognition Tool (CERT) to Help Patients Recognize When to Seek Medical Advice. International Journal of COPD, 2022, Volume 17, 213-222.	0.9	5
75	Reanalysis of the Japanese experience using the combined COPD assessment of the 2011 GOLD classification. Respiratory Investigation, 2014, 52, 129-135.	0.9	4
76	A Prospective Cohort Study to Assess Obstructive Respiratory Disease Phenotypes and Endotypes in Japan: The TRAIT Study Design. International Journal of COPD, 2021, Volume 16, 1813-1822.	0.9	4
77	Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX Trial. Advances in Therapy, 2021, 38, 4815-4835.	1.3	4
78	Clinical Development and Research Applications of the Chronic Obstructive Pulmonary Disease Assessment Test. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1058-1067.	2.5	3
79	Investigation of the Clinical, Radiological and Biological Factors Associated with Disease Progression, Phenotypes and Endotypes of COPD in China (COMPASS): study design, protocol and rationale. ERJ Open Research, 2021, 7, 00201-2021.	1.1	3
80	Factors affecting brain structure in smoking-related diseases: Chronic Obstructive Pulmonary Disease (COPD) and coronary artery disease. PLoS ONE, 2021, 16, e0259375.	1.1	3
81	Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model. International Journal of COPD, 2021, Volume 16, 3105-3118.	0.9	2
82	Treatment Preferences of Patients with Chronic Obstructive Pulmonary Disease: Results from Qualitative Interviews and Focus Groups in the United Kingdom, United States, and Germany. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2021, 8, 19-30.	0.5	1
83	MEASURING SUCCESS OF ASTHMA THERAPY. Clinical and Experimental Allergy, 1993, 23, 62-62.	1.4	0
84	Inhaled triamcinolone did not slow the decline in pulmonary function in patients with COPD. ACP Journal Club, 2001, 135, 21.	0.1	0
85	Applying key learnings from the EMAX trial to clinical practice and future trial design in COPD. Respiratory Medicine, 2022, , 106918.	1.3	0